MTE #44 - Management of MASLD/MASH: There's an App for That

Nov 13 2023
Room 104 - Hynes Convention Center
12:30 - 1:15 PM EST

Speakers

Sonal Kumar

Weill Cornell Medical College

Naim Alkhouri

Arizona Liver Health

Description

Despite the anticipated FDA approval of the first MASH drug by the end of 2023, lifestyle interventions aiming at significant weight loss will remain cornerstone therapy for this disease. So far dietary interventions at large scale have failed to show sustainable longterm outcomes and modern weight loss medications are not widely available or affordable. Digital therapeutic platforms have the potential to overcome the challenges MASH patients face in making lifestyles changes and improving liver health.

Objectives

  • To introduce a conceptual framework of applying digital therapeutic platforms for MASLD care
  • To share knowledge from investigators utilizing digital therapeutics in the management of patients with MASLD/MASH